Treatment strategies for cystic fibrosis: What's in the pipeline?

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 7, 2009, Pages 1191-1202

  Frerichs, Carley ^b   Smyth, Alan ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NONE

Author keywords

Aerosolised antibiotics; Anti inflammatory; CFTR modulation; Cystic fibrosis; Mucus regulation; New therapies

Indexed keywords

ALTU 135; AMIKACIN; AMILORIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINE; CEFACLOR; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; CURCUMIN; DENUFOSOL; DURAMYCIN; FLUCLOXACILLIN; FOSFOMYCIN; KREON; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MANNITOL; MERISPASE; MIGLUSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; PANCREAS ENZYME; PTC 124; SILDENAFIL; TOBRAMYCIN; TRIZYTEK; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VX 770; VX 809; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ENZYME; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC THERAPY; CHRONIC LUNG DISEASE; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG MECHANISM; ENZYME THERAPY; GENE SEQUENCE; HAEMOPHILUS INFECTION; HUMAN; LUNG FUNCTION; LUNG INFECTION; MALABSORPTION; MUCOCILIARY CLEARANCE; NEPHROTOXICITY; NONHUMAN; PROGNOSIS; PSEUDOMONAS INFECTION; RECURRENT INFECTION; REVIEW; SIDE EFFECT; SPUTUM; STAPHYLOCOCCUS INFECTION; SYSTEMIC DISEASE; GENE THERAPY; GENETICS; MUCUS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENZYMES; GENE THERAPY; HUMANS; MUCUS;

EID: 67649550403     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902928896     Document Type: Review

References (78)

1. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-526
2. Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2. Prevention. Thorax 2007;62:723-732 • Important series of review articles on the management of pulmonary exacerbations in CF.
3. Proesmans M, Vermeulen F, De Boeck K. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur J Pediatr 2008;167:839-849 • A useful review of novel strategies evolving in the management of CF.
4. Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ 2007;335:1255-1259
5. Doull IJM. Recent advances in cystic fibrosis. Arch Dis Child 2001;85:62-66
6. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007;62:360-367 • Important series of review articles on the management of pulmonary exacerbations in CF.
7. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23:146-158 (Pubitemid 38088512)
8. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571-1572
9. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951 (Pubitemid 37267172)
10. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100 (Pubitemid 34809519)
11. Al Aloul M, Crawley J, Winstanley C, et al. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 2004;59:334-336 (Pubitemid 38496753)
12. Littlewood JM, Wolfe SP, Conway SP. State of the art. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol 2009;41:35-49
13. US CF Foundation. Patient registry. Annual Data Report 2007. Bethesda: Cystic Fibrosis Foundation, 2008
14. Lindblad A, Glaumann H, Strandvik B, et al. Natural history of liver disease in cystic fibrosis. Hepatology 1999;30:1151-1158 (Pubitemid 29510852)
15. Akata D, Akhan O. Liver manifestations of cystic fibrosis. Eur J Radiol 2007;61:11-17 (Pubitemid 46038030)
16. Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros 2004;3:209-222 (Pubitemid 40227489)
17. UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Bone Mineralisation in Cystic Fibrosis. London: UK Cystic Fibrosis Trust, 2007 •• Key guideline.
18. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005;90:1888-1896 •• Key guideline.
19. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996;21:153-158 (Pubitemid 26127307)
20. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; Issue 3. Art. No.:CD001912. DOI: 10.1002/14651858.CD001912 •• Key systematic review.
21. UK Cystic Fibrosis Trust Antibiotic Group. Antibiotic Treatment for Cystic Fibrosis (3rd edition). London: UK Cystic Fibrosis Trust, 2009 •• Key guideline.
22. Rayner RJ, Hiller EJ, Ispahani P, Baker M. Haemophilus infection in cystic fibrosis. Arch Dis Child 1997;65:255-258 (Pubitemid 20108890)
23. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980;28:546-556 (Pubitemid 10102095)
24. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7:523-530
25. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006; Issue 1. Art. No.:CD004197.pub2. DOI: 10.1002/14651858.CD004197.pub2 •• Key systematic review.
26. Steinkamp G, Tummler B, Malottke R, von der Hardt H. Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis. Arch Dis Child 1989;64:1022-1028 (Pubitemid 19177590)
27. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-969 •• Key guideline. (Pubitemid 350127838)
28. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; Issue 3. Art. No.:CD001021. DOI: 10.1002/14651858.CD001021 •• Key systematic review.
29. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756 •• Major clinical trial that has altered clinical practice. (Pubitemid 37430625)
30. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-473 (Pubitemid 32523640)
31. Southern KW, Barker PM, Solis-Moya A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004; Issue 2. Art. No.:CD002203. DOI: 10.1002/14651858.CD002203.pub2 •• Key systematic review.
32. Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005;365:573-578 •• Major clinical trial that has altered clinical practice. (Pubitemid 40247913)
33. Chan GLC. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. DICP 1989;23:788-794 (Pubitemid 19253971)
34. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30 •• Major clinical trial that has altered clinical practice. (Pubitemid 29024680)
35. Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-313 (Pubitemid 46608898)
36. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-928 •• Important clinical trial that is likely to alter clinical practice.
37. Retsch-Bogart GZ, Burns JL, Otto KL, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008;43:47-58
38. Oermann C, McCoy K, Retsch-Bogart G, et al. Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data. J Cyst Fibros 2008;7(Suppl 2):S25
39. Goldman MH, Pitt T. Lack of emergence of antimicrobial resistance of Pseudommonas aeruginosa after six months of inhalation of dry powder colistimethate. Pediatr Pulmonol 2008;43:331
40. Lee TWR, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem J 2005;387:1-15 •• Important review of potential therapeutic targets in CF. (Pubitemid 40524069)
41. Available from: http://www.cfgenetherapy. org.uk/
42. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007;28:334-341 •• Important review of emerging therapies, targeted at molecular mechanisms, in CF. (Pubitemid 47016687)
43. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-727 •• Important clinical trial that led to an entirely new treatment strategy for CF (and possibly for other conditions).
44. Clancy JP, Konstan MW, Rowe SM, et al. A phase 2 study of PTC124 in CF patients harboring premature stop mutations. Pediatr Pulmonol 2006;41(Suppl 29):291
45. Storey S, Wald G. Novel agents in cystic fibrosis. Nat Rev Drug Discov 2008;7:555-556 • A useful summary of new treatments in CF and their progress in clinical trials. (Pubitemid 351927720)
46. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005;60:55-59 (Pubitemid 40101019)
47. Norez C, Antigny F, Noel S, et al. A CF respiratory epithelial cell chronically treated by miglustat acquires a non-CF like phenotype. Am J Respir Cell Mol Biol 2009;2008-0285OC
48. Bye PTP, Elkins MR. Other mucoactive agents for cystic fibrosis. Paediatr Respir Rev 2007;8:30-39 (Pubitemid 46523788)
49. Burrows EF, Southern KW. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 2006; Issue 3. Art. No.:CD005087. DOI: 10.1002/14651858.CD005087.pub2 •• Key systematic review.
50. Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in beta ENaC-overexpressing mice. Am J Respir Crit Care Med 2008;178:1245-1256
51. Oliynyk I, Varelo G, Roomans GM, Johannesson M. Moli1901 (duramycin) increases chloride transport in cystic fibrosis airway epithelial and pancreatic cell lines. J Cyst Fibros 2008;7(Suppl 2):S23
52. Grasemann H, Stehling F, Brunar H, et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007;131:1461-1466 (Pubitemid 46762353)
53. Kellerman D, Rossi Mospan A, Engels J, et al. Denufosol: a review of studies with inhaled P2Y2 agonists that led to Phase 3. Pulm Pharmacol Ther 2008;21:600-607 (Pubitemid 351970709)
54. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-1396 (Pubitemid 351892995)
55. Pharmaxis. Press release 04 April 2008. Available from: http://www.pharmaxis.com. au/library/2008-04-04-CF203.pdf. Pharmaxis web site [online] 2008
56. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2007; Issue 4. Art. No.:CD001505. DOI: 10.1002/14651858.CD001505.pub2 •• Key systematic review.
57. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 1999; Issue 4. Art. No.:CD000407. DOI: 10.1002/14651858. CD000407 •• Key systematic review.
58. Balfour-lynn I, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2009; Issue 1. Art. No.:CD001915. DOI: 10.1002/14651858.CD001915.pub2 •• Key systematic review.
59. Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006;173:1356-1362 •• Major clinical trial that has altered clinical practice. (Pubitemid 43900710)
60. Graff GR, Weber A, Wessler-Starman D, Smith AL. Montelukast pharmacokinetics in cystic fibrosis. J Pediatr 2003;142:53-56 (Pubitemid 36106388)
61. Schmitt-Grohe S, Eickmeier O, Schubert R, et al. Anti-inflammatory effects of montelukast in mild cystic fibrosis. Ann Allergy Asthma Immunol 2002;89:599-605 (Pubitemid 36183850)
62. Stelmach I, Korzeniewska A, Smejda K, et al. Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis. Pneumonol Alergol Pol 2004;72:85-89 (Pubitemid 39093498)
63. Jones AP, Wallis C, Kearney CE. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2003; Issue 3. Art. No.:CD001127. DOI: 10.1002/14651858.CD001127. (Updated 2006) •• Key systematic review.
64. Johnson CA, Butler SM, Konstan MW, et al. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. J Pediatr 1999;134:734-739
65. Quan J, Tiddens HAWM, Sy JP, et al. A two-year randomised placebo controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820 (Pubitemid 34014460)
66. Berge MT, Wiel E, Tiddens HA, et al. DNase in stable cystic fibrosis infants: a pilot study. J Cyst Fibros 2003;2:183-188 (Pubitemid 37376495)
67. Wark P, McDonald VM, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2005; Issue 3. Art. No.:CD001506. DOI: 10.1002/14651858.CD001506.pub2 •• Key systematic review.
68. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240 •• Major clinical trial that has altered clinical practice. (Pubitemid 43113028)
69. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250 (Pubitemid 43113029)
70. Smyth RL, Ashby D, O'Hea U, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995;346:1247-1251 • Important safety study.
71. Borowitz D, Goss CH, Limauro S, et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr 2006;149:658-662 (Pubitemid 44767694)
72. Lenoir G, Dubray C, Hubert D, et al. Phase II study in young CF adults with the recombinant acid lipase MERISPASE® . J Cyst Fibros 2008;7(Suppl 2):S29
73. Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 1999; Issue 3. Art. No.:CD000222. DOI: 10.1002/14651858.CD000222 •• Key systematic review.
74. UK Cystic Fibrosis Trust Diabetes Working Group. Management of Cystic Fibrosis related diabetes mellitus. London: UK Cystic Fibrosis Trust, 2004 •• Key guideline.
75. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2005; Issue 3. Art. No.:CD004730. DOI: 10.1002/14651858.CD004730.pub2 •• Key systematic review.
76. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001;24:1706-1710 (Pubitemid 33716470)
77. Aris RM, Lester GE, Caminiti M, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004;169:77-82 (Pubitemid 38233892)
78. Hyde SC, Gill DR. Ignoring the nonsense: a phase II trial in cystic fibrosis. Lancet 2008;372:691-692